| Prev Close | 397.78 |
| Open | 400.40 |
| Day Low/High | 392.99 / 401.99 |
| 52 Wk Low/High | 182.07 / 456.23 |
| Volume | 716.81K |
DexCom, Inc. (DXCM)
396.85
0.93
0.23
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 96.18B |
| Market Cap | 38.04B |
| P/E Ratio | 151.69 |
| Div & Yield | N.A. (N.A) |
Latest News
DexCom Shares Could Weaken Still Further in the Months Ahead
Investors continue to be more aggressive sellers of DXCM.
DexCom Could Work Itself Lower in the Weeks Ahead
A 'careful' approach is in order for traders.
Go Slow on Any DexCom Purchases for Now
Let's review the charts and indicators.
Jim Cramer: Health Care Stocks, the Election and the Perfect Setup
Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.
Jim Cramer: Follow the Lead of Elon Musk and Tim Cook: Split
Both Apple and Tesla are chopping shares into pieces, which will let individual investors have a shot at buying them.
DexCom Looks Poised to Correct or Pull Back on Weakening Momentum
The charts of the maker of medical devices for monitoring diabetes suggest a pause in its shares may be ahead.
Danger Beneath the Waves, Chip Stocks Ahoy, Fiscal Battle, Sizing Up Starbucks
Negotiations on the next round of stimulus, more so than tension between Washington and Beijing, and more so than earnings season, will control short-term financial market performance.
DexCom Stock Has Been Soaring: Here's What Could Happen Next
The glucose monitoring company is in Jim Cramer's Covid-19 index.
Jim Cramer: Here's the Cramer Covid-19 Index Top 10 Names and Their Performance
There are simply an immense number of health and technology and safety companies coupled with businesses that thrive when you have to stay home.
Small-Caps Roar, Bets Against the Market, Trading Nvidia
Money movers are not buying protection for individual names, but they are starting to bet against the market en masse, while the Russell 2000 ran up 4% on Monday.
Jim Cramer: Rate Cut No Cure for Coronavirus
But don't throw up your arms yet -- here are names that could be golden opportunities.
Why Worry About Negative Arguments When the Price Action Says They Don't Matter?
The reason that the coronavirus hasn't mattered to the market is because the market keeps going up.
Coronavirus Spreads, Reducing 'Big Oil', 4 Stocks to Watch, Adding Store Capital
Newly confirmed cases of the Covid-19 virus spiked from Hubei Province in China, where the city of Wuhan is located. The number of related deaths increased as well.
Healthy Upside Potential In Medical Devices and Services Stocks
Some of the best opportunities are in lesser-known niche markets such as medical devices and services.
Can DexCom Trade Still Higher or Did We Witness a Blow Off?
Let's check the charts and indicators before answering the $64,000 question.
Dexcom Looks Poised to Build on Its Big Gap Up
The maker of glucose monitoring equipment saw its shares shoot higher last week on a big earnings beat and the rise may not be over.
China Gets Serious, Trading Roku: Market Recon
As for pressure on the Chinese side, I think a September 17.8% decline in exports to the U.S. compounded on top of a 22% decline in August speaks for itself.
U.S. Treasury Yield Curve, Oil Market Valuations, Trading Adobe: Market Recon
OPEC forecasts declining demand for OPEC oil, not a decline in global demand. That distinction is key.
Dexcom Looks Like It Can Finally Break Out on the Topside
Let's check the charts and indicators on the glucose-monitoring company.
Jim Cramer: Blockbuster Ideas That I Know Would Move Apple's Needle
What would the people who help determine AAPL's stock price really want?
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
A Technical Strategy for Tandem Diabetes Care
Are we late to the game with the stock up so much?
The Three Bullish Charts of DexCom
With more gains likely on the charts let's come up with a strategy to take advantage of this opportunity.
Jim Cramer: We Remain Excited About Abbott Laboratories for Action Alerts Plus
Jim Cramer explains why his Action Alerts Plus charitable portfolio is hanging on to Abbott Laboratories.
Apple Watch Appears on Its Way to Becoming a $6 Billion Business
After a slump early last year, the smartwatch's sales have been rebounding. New features unveiled at Apple's WWDC conference could aid its momentum later this year.
Jim Cramer: Report of Apple's Diabetes Test Isn't a Reason to Own the Stock
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said reports of Apple developing a diabetes testing product is not a reason to own the stock.
Trader's Daily Notebook: Worried About Volume? Just Let It Go
Old-line momentum favorites fare well.
